Cann Group Ltd. · ASX:CAN
Cann — NWR Communications Virtual Health Conference (May 2020)
16 slides from Cann's conference presentation, May 4, 2020
Slide 1: Cann to present at NWR Virtual Health Conference
ASX ANNOUNCEMENT 4 May 2020 CANN TO PRESENT AT NWR VIRTUAL HEALTH CONFERENCE 4 May 2020 – Melbourne-based Cann Group (“Company”) is pleased to provide an opportunity for shareholders and investors to join a virtual presentation by CEO Peter Crock, who will present at the NWR Virtual Health Conferenc
Slide 2: Investor presentation
Investor presentation 1 May 2020
Slide 3: Disclaimer
Disclaimer IMPORTANT: You must read the following before continuing. Summary Information This Investor Update (“IU”) has been prepared by Cann Group Limited (ACN 603 949 739) (the “Company”). The following disclaimer applies to this document and any information provided regarding the information con
Slide 4: Cann is a fully integrated medicinal cannabis company
Cann is a fully integrated medicinal cannabis company • First Australian company to secure cultivation licence & permit • Headquartered in Melbourne – two existing production & research facilities, with plans to rapidly scale-up via new state-of-the-art Mildura development • Successful track record
Slide 5: Global update – the opportunity for GMP medicinal cannabis products
Global update – the opportunity for GMP medicinal cannabis products • European market continues to expand, with local production/supply currently Export potential growing across worldwide unable to meet European demand Medicinal cannabis market size forecast - Canadian licensed producers continue to
Slide 6: Australian industry continues positive momentum
Australian industry continues positive momentum • 92 licences issued to late January 2020 but only a few companies actually producing to commercial scale or to GMP requirements Estimated that only Patient numbers • Prescription system streamlined to allow prescribers to simultaneously apply for both
Slide 7: Commercial activity gaining momentum
Commercial activity gaining momentum • National distribution agreement with Symbion Pty Ltd for Cann’s full range of imported & locally manufactured products within Australia – Symbion supplies 4,000 retail pharmacies & 1,300 hospitals throughout Australia • Five-year supply agreement signed with Pu
Slide 8: Cann Group has established a vertically integrated supply chain
Cann Group has established a vertically integrated supply chain • Cultivars – International genetics program has allowed Cann to test, identify & focus on strains with the most compelling attributes for cultivation at scale • Flexible cultivation/production facilities – Existing facilities currently
Slide 9: Existing production capability & near-term capacity expansion strategy
Existing production capability & near-term capacity expansion strategy • Cultivation continuing at Cann’s Southern & Northern facilities in Melbourne • The existing facilities have production capacity of 1,200kg of dried flower per annum • 66 harvests completed to date • Working with Agriculture Vic
Slide 10: Response to COVID-19
Response to COVID-19 • As a supplier of medical products to Australian patients Cann Group is considered an essential service • Appropriate changes implemented which allows for continued operations throughout the pandemic • Includes a shift-based system for cultivation operations with other staff wo
Slide 11: Cann launches its first locally produced GMP product
Cann launches its first locally produced GMP product • Using IDT Australia’s methods & processes, the first large scale production runs of Australian grown & manufactured value-added GMP products have been completed • Dried cannabis flower & cannabis oil from Cann’s Australian grown cannabis – shelf
Slide 12: Updated business plan delivers greater certainty & less risk
Updated business plan delivers greater certainty & less risk The Board & Management have developed an updated business plan that focuses on: • Initially meeting Australian domestic demand while export markets continue to be developed • Short term importation of biomass expected to result in increase
Slide 13: Mildura facility – world-class design & technology
Mildura facility – world-class design & technology • Utilising design & workflow from Aurora’s SKY Class facilities to drive efficiency & reduce biomass production costs • Revised construction plan more closely aligns capacity with anticipated demand & lowers capital investment risk • First sales fr
Slide 14: Mildura funding & financial metrics
Mildura funding & financial metrics • Cann’s board is adopting a prudent approach to assessing various funding options for the Mildura facility • Design & costing parameters set for both phases of Stage 1 • Discussions ongoing with Tier 1 Australian bank on loan facility to help fund Stage 1A expans
Slide 15: Cann is strongly positioned in a growing global market
Cann is strongly positioned in a growing global market • The global medicinal cannabis market is forecast to experience strong growth, based on expanding number of legalised markets; increase in patient numbers; & a growing body of medical evidence to support treatment of indications • As markets de
Slide 16: Contacts
CONTACTS: Clive Fanning Head of Investor Relations Cann Group Limited +61 (0)498 000 762 contact@canngrouplimited.com Peter Crock CEO Cann Group Limited +61 (0) 419 307 467 contact@canngrouplimited.com 15
Cann Group — NWR Communications Virtual Health Conference (May 2020) on 6ix